LifeSci Capital Believes Celldex (NASDAQ: CLDX) Still Has Room to Grow
In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Celldex (CLDX – Research Report), with a price target of $32.00. The company’s shares closed last Tuesday More »
Raymond James Believes Dell Technologies (NYSE: DELL) Won’t Stop Here
In a report released yesterday, Simon Leopold from Raymond James initiated coverage with a Buy rating on Dell Technologies (DELL – Research Report) and a price target of $85.00. The company’s shares More »
